Trevi Therapeutics stock (TRVI) earns a Buy rating as Haduvio advances toward phase 3 for chronic cough in IPF. Read the full ...
Nerandomilast, a PDE4 inhibitor, has shown significant efficacy in progressive pulmonary fibrosis (PPF), offering an ...
Nerandomilast, a PDE4B inhibitor, is a new treatment option for IPF, showing better tolerability than nintedanib and ...
Our latest symposium review summarises several Boehringer Ingelheim presentations and posters on the role of nerandomilast, an oral investigational phosphodiesterase 4B inhibitor, for the treatment of ...
With phase I/II data in hand, Taiho Pharmaceutical Co. Ltd. and Cullinan Therapeutics Inc. began filing a rolling NDA to the U.S. FDA for accelerated approval of zipalertinib to treat patients with ...
Treatment for progressive pulmonary fibrosis (PPF) depends on the underlying etiology of the condition, symptom severity at diagnosis, and the presence of comorbidities. PPF refers to a progressive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback